A Venture Studio with Big Pharma Backing Seeks to Fix Drug Development with AI

Dr. Amar Drawid, an industry veteran who has worked in data science leadership with top biopharmaceutical companies. He explores the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.

Mati Gill, CEO of AION Labs, brings extensive experience in the pharmaceutical and biotech industries. Prior to leading AlON Labs, Mati spent 11 years at Teva Pharmaceuticals, where he served as the Head of Government Affairs, Corporate and International Markets. During his tenure at Teva, he developed the company's innovative strategy and built a robust network of partnerships. Mati holds an MBA and a BA in Law from Reichman University, underscoring his expertise in both business and legal aspects of the industry.